Genetic susceptibility of COVID-19: a systematic review of current evidence

Springer Science and Business Media LLC
SeyedAhmad SeyedAlinaghi1, Mohammad Mehrtak2, Mehrzad MohsseniPour3, Pegah Mirzapour1, Alireza Barzegary4, Pedram Habibi1, Banafsheh Moradmand-Badie5, Amir Masoud Afsahi6, Amirali Karimi7, Mohammad Heydari8, Esmaeil Mehraeen8, Omid Dadras9, Jean‐Marc Sabatier10, Fabrí­cio Azevedo Voltarelli11
1Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
2Healthcare Services Management, School of Medicine and Allied Medical Sciences, Ardabil University of Medical Sciences, Ardabil, Iran
3Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
4School of Medicine, Islamic Azad University, Tehran, Iran
5Black Dog Institute, University of New South Wales, Sydney, Australia
6Department of Radiology, School of Medicine, University of California, San Diego (UCSD), San Diego, CA, USA
7School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
8Department of Health Information Technology, Khalkhal University of Medical Sciences, 1419733141, Khalkhal, Iran
9Department of Global Health and Socioepidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
10Institut deNeuro-Physiopathologie (INP), UMR 7051, Faculté de Pharmacie, Université Aix-Marseille, 27 Bd Jean Moulin, 13385, Marseille Cedex, France
11Graduation Program of Health Sciences, Faculty of Medicine, Federal University of Mato Grosso, Cuiabá, Brazil

Tóm tắt

Abstract Introduction

While COVID-19 pandemic continues to spread worldwide, researchers have linked patterns of traits to poor disease outcomes. Risk factors for COVID-19 include asthma, elderly age, being pregnant, having any underlying diseases such as cardiovascular disease, diabetes, obesity, and experiencing lifelong systemic racism. Recently, connections to certain genes have also been found, although the susceptibility has not yet been established. We aimed to investigate the available evidence for the genetic susceptibility to COVID-19.

 Methods

This study was a systematic review of current evidence to investigate the genetic susceptibility of COVID-19. By systematic search and utilizing the keywords in the online databases including Scopus, PubMed, Web of Science, and Science Direct, we retrieved all the related papers and reports published in English from December 2019 to September 2020.

 Results

According to the findings, COVID-19 uses the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. Previous studies have shown that people with ACE2 polymorphism who have type 2 transmembrane serine proteases (TMPRSS2) are at high risk of SARS-CoV-2 infection. Also, two studies have shown that males are more likely to become infected with SARS-CoV-2 than females. Besides, research has also shown that patients possessing HLA-B*15:03 genotype may become immune to the infection.

 Conclusion

Combing through the genome, several genes related to immune system’s response were related to the severity and susceptibility to the COVID-19. In conclusion, a correlation was found between the ACE2 levels and the susceptibility to SARS-CoV-2 infection.

Từ khóa


Tài liệu tham khảo

WHO. WHO director-general’s opening remarks at the media briefing on COVID-19. 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19. Accessed on 11 Mar 2020.

SeyedAlinaghi S, Abbasian L, Solduzian M, Ayoobi Yazdi N, Jafari F, Adibimehr A, Farahani A, Salami Khaneshan A, Ebrahimi Alavijeh P, Jahani Z, Karimian E, Ahmadinejad Z, Khalili H, Seifi A, Ghiasvand F, Ghaderkhani S, Rasoolinejad M. Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study. Eur J Med Res. 2021;26(1):41. https://doi.org/10.1186/s40001-021-00513-x.

Mehraeen E, Hayati B, Saeidi S, Heydari M, SeyedAlinaghi S. Self-care instructions for people not requiring hospitalization for Coronavirus disease 2019 (COVID-19). Arch Clin Infect Dis. 2020;15(COVID-19):e102978.

Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. Int J Antimicrob Agents. 2020;56(4):106143.

SeyedAlinaghi S, Ghadimi M, Hajiabdolbaghi M, Rasoolinejad M, Abbasian L, Nezhad MH, et al. Prevalence of COVID-19-like symptoms among people living with HIV, and using antiretroviral therapy for prevention and treatment. Curr HIV Res. 2020;18:373.

Seyed ASA, Karimi A, Shobeiri P, Nowroozi A, Mehraeen E, Afsahi AM, et al. Psychological symptoms of COVID-19 epidemic: a systematic review of current evidence. Psihologija. 2020;54:35.

Ghiasvand F, Miandoab SZ, Harandi H, Golestan FS, Alinaghi SAS. A patient with COVID-19 disease in a referral hospital in Iran: a typical case. Infect Disord Drug Targets. 2020;20(4):559–62. https://doi.org/10.2174/1871526520666200429115535.

Mehraeen E, Behnezhad F, Salehi MA, Noori T, Harandi H, SeyedAlinaghi S. Olfactory and gustatory dysfunctions due to the Coronavirus disease (COVID-19): a review of current evidence. Eur Arch Otorhinolaryngol. 2020;278:1–6.

Ghiasvand F, Ghadimi M, Ghadimi F, Safarpour S, Hosseinzadeh R, SeyedAlinaghi S. Symmetrical polyneuropathy in Coronavirus disease 2019 (COVID-19). IDCases. 2020;21:e00815.

WHO. WHO Coronavirus disease (COVID-19) dashboard: https://covid19.who.int/. Accessed 01 Apr 2020.

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–60.

Sadr S, SeyedAlinaghi S, Ghiasvand F, Hassan Nezhad M, Javadian N, Hossienzade R, et al. Isolated severe thrombocytopenia in a patient with COVID-19: a case report. IDCases. 2020;21:e00820.

Ghiasvand F, SeyedAlinaghi S. Isolated anosmia as a presentation of COVID-19: an experience in a referral hospital. Infect Disord Drug Targets. 2020;20(3):350.

Ahmadinejad Z, Salahshour F, Dadras O, Rezaei H, Alinaghi S. Pleural effusion as a sign of Coronavirus disease 2019 (COVID-19) pneumonia: a case report. Infect Disord Drug Targets. 2020. https://doi.org/10.2174/1871526520666200609125045.

Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117(21):11727.

Mollica V, Rizzo A, Massari F. The pivotal role of TMPRSS2 in Coronavirus disease 2019 and prostate cancer. Future Oncol. 2020;16(27):2029–33.

Deng Q, Rasool RU, Russell RM, Natesan R, Asangani IA. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience. 2021;24(3):102254.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80e8.

Shirato K, Kawase M, Matsuyama S. Wild-type human Coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology. 2018;517:9–15.

Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afsahi AM, Dadras O, et al. Predictors of mortality in patients with COVID-19—a systematic review. Eur J Integr Med. 2020;40:101226.

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS Coronavirus. Nature. 2003;426(6965):450–4.

Mehraeen E, Seyed Alinaghi SA, Nowroozi A, Dadras O, Alilou S, Shobeiri P, et al. A systematic review of ECG findings in patients with COVID-19. Indian Heart J. 2020;72(6):500–7.

Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome Coronavirus spike protein. J Virol. 2014;88(2):1293–307.

Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome Coronavirus entry. J Virol. 2012;86(12):6537–45.

Bertram S, Heurich A, Lavender H, Gierer S, Danisch S, Perin P, et al. Influenza and SARS-Coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS ONE. 2012;7(4):e35876.

Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020;18(1):216.

Cattrini C, Bersanelli M, Latocca MM, Conte B, Vallome G, Boccardo F. Sex hormones and hormone therapy during COVID-19 pandemic: implications for patients with cancer. Cancers. 2020;12(8):2325.

Bennani NN, Bennani-Baiti IM. Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy. Ann Oncol. 2020;31(11):1585–6.

Schuler BA, Habermann AC, Plosa EJ, Taylor CJ, Jetter C, Kapp ME, et al. Age-related expression of SARS-CoV-2 priming protease TMPRSS2 in the developing lung. bioRxiv. 2020. https://doi.org/10.1101/2020.05.22.111187.

Abhari S, Kawwass JF. Endometrial susceptibility to SARS CoV-2: explained by gene expression across the menstrual cycle? Fertil Steril. 2020;114(2):255–6.

Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel Coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6(1):1–4.

Casanova J-L, Su HC, Effort CHG. A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell. 2020;181:1194.

Debnath M, Banerjee M, Berk M. Genetic gateways to COVID-19 infection: implications for risk, severity, and outcomes. FASEB J. 2020;34:8787.

Devaux CA, Rolain J-M, Raoult D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53:425.

Fakhouri EW, Peterson SJ, Kothari J, Alex R, Shapiro JI, Abraham NG. Genetic polymorphisms complicate COVID-19 therapy: pivotal role of HO-1 in cytokine storm. Antioxidants. 2020;9(7):636.

Fujikura K, Uesaka K. Genetic variations in the human severe acute respiratory syndrome Coronavirus receptor ACE2 and serine protease TMPRSS2. J Clin Pathol. 2020;74:307.

Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int J Mol Sci. 2020;21(10):3474.

Giudicessi JR, Roden DM, Wilde AA, Ackerman MJ. Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans. Heart Rhythm. 2020;17:1487.

Godri Pollitt KJ, Peccia J, Ko AI, Kaminski N, Dela Cruz CS, Nebert DW, et al. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission. Hum Genomics. 2020;14:1–7.

Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020;18(1):1–8.

Junejo Y, Ozaslan M, Safdar M, Khailany RA, Rehman S, Yousaf W, et al. Novel SARS-CoV-2/COVID-19: origin, pathogenesis, genes and genetic variations, immune responses and phylogenetic analysis. Gene Rep. 2020;20:100752.

Kachuri L, Francis SS, Morrison M, Bossé Y, Cavazos TB, Rashkin SR, et al. The landscape of host genetic factors involved in infection to common viruses and SARS-CoV-2. medRxiv. 2020;10:59.

LoPresti M, Beck DB, Duggal P, Cummings DA, Solomon BD. The role of host genetic factors in Coronavirus susceptibility: review of animal and systematic review of human literature. medRxiv. 2020;3:35.

Sanchez-Gonzalez MA, Moskowitz D, Issuree PD, Yatzkan G, Rizvi S, Day K. A pathophysiological perspective on COVID-19’s lethal complication: from viremia to hypersensitivity pneumonitis-like immune dysregulation. Infect Chemother. 2020;52:e31.

Sheikh JA, Singh J, Singh H, Jamal S, Khubaib M, Kohli S, et al. Emerging genetic diversity among clinical isolates of SARS-CoV-2: lessons for today. Infect Genet Evol. 2020;84:104330.

Sironi M, Hasnain SE, Phan T, Luciani F, Shaw M-A, Sallum MA, et al. SARS-CoV-2 and COVID-19: a genetic, epidemiological, and evolutionary perspective. Infect Genet Evol. 2020;84:104384.

Lopera Maya EA, van der Graaf A, Lanting P, van der Geest M, Fu J, Swertz M, et al. Lack of association between genetic variants at ACE2 and TMPRSS2 genes involved in SARS-CoV-2 infection and human quantitative phenotypes. Front Genet. 2020;11:613.

Strafella C, Caputo V, Termine A, Barati S, Gambardella S, Borgiani P, et al. Analysis of ACE2 genetic variability among populations highlights a possible link with COVID-19-related neurological complications. Genes. 2020;11:741.

Torre-Fuentes L, Matías-Guiu J, Hernández-Lorenzo L, Montero-Escribano P, Pytel V, Porta-Etessam J, et al. ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain. J Med Virol. 2020;93:863.

von der Thüsen J, van der Eerden M. Histopathology and genetic susceptibility in COVID-19 pneumonia. Eur J Clin Investig. 2020. https://doi.org/10.1111/eci.13259.

Vuitton DA, Vuitton L, Seillès E, Galanaud P. A plea for the pathogenic role of immune complexes in severe COVID-19. Clin Immunol. 2020;217:108493.

Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985.

Baker SA, Kwok S, Berry GJ, Montine TJ. Angiotensin-converting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation. PLoS ONE. 2021;16(2):e0247060.

Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425–35.

Song H, Seddighzadeh B, Cooperberg MR, Huang FW. Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells. bioRxiv. 2020. https://doi.org/10.1101/2020.04.24.056259.

Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40:905.

Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202(5):756–9.

Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14.

Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin–angiotensin system. J Endocrinol. 2013;216(2):R1-17.

Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in Coronavirus disease 2019 (COVID-19)? Clin Chem Lab Med. 2020;58:1415.

Chaudhary M. COVID-19 susceptibility: potential of ACE2 polymorphisms. Egypt J Med Human Genet. 2020;21(1):1–8.

Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324(2):168–77.

Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801–3.

Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–67.

Godri Pollitt KJ, Peccia J, Ko AI, Kaminski N, Dela Cruz CS, Nebert DW, et al. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission. Hum Genom. 2020;14(1):17.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả